Connect with us

Foreign

South Africa’s Aspen inks deal with J&J for African anti-Covid jab

Published

on

South Africa’s Aspen inks deal with J&J for African anti-Covid jab

South African pharmaceutical giant Aspen said Tuesday that it had struck a deal in principle with US-based Johnson & Johnson, paving the way for an antiCovid vaccine “made in Africa for Africa.”

“Today we are pleased to announce Johnson & Johnson’s intention to grant Aspen the rights to manufacture and sell Aspen’s own brand of vaccine in Africa,” Aspen CEO Stephen Saad said in a statement.

The preliminary agreement “will form the basis for the negotiation of a definitive agreement on the manufacture and sale of an Aspen-brand Covid-19 vaccine throughout Africa,” the statement said.

“In addition, Johnson & Johnson would license Aspen the enabling intellectual property for this purpose,” the company added.

Africa has the lowest vaccination rate in the world with less than seven percent of people fully vaccinated, mainly due to a profound inequality of access compared to rich countries.

South Africa and India have led efforts to pressure advanced nations to lift intellectual property protections on coronavirus vaccines, in hopes of producing low-cost generic versions for poorer countries.

“This announcement will make an important contribution to addressing vaccine inequality and building Africa’s capacity to meet its own vaccine needs now and in the future,” South African President Cyril Ramaphosa said in the statement.

And Matshidiso Moeti, the World Health Organization’s regional director for Africa, called it “an important step toward increasing Africa’s manufacturing capacity and driving increased access to vaccines.”

Aspen’s announcement follows the detection of the latest Covid-19 variant, dubbed Omicron, by South African scientists, triggering a new wave of global anxiety about the virus.

The company already packages the J&J vaccines at a factory in the southern South African city of Gqeberha, but until now it did not have a patent agreement with the developer to give it sales and pricing power.

Aspen, Africa’s largest drug maker, says it has packaged more than 100 million doses in South Africa, nearly all for use on the continent.

It says it could produce up to 300 million doses of J&J a year, with the goal of increasing that capacity to 700 million by January 2023.

Source Credit: TheGuardian

Short Link: https://wp.me/pcj2iU-3F1t

NNN is a Nigerian online news portal that publishes breaking news in Nigeria, and across the world. We are honest, fair, accurate, thorough and courageous in gathering, reporting and interpreting news in the best interest of the public, because truth is the cornerstone of journalism and we strive diligently to ascertain the truth in every news report. Contact: editor @ nnn.ng. Disclaimer.